If finalized, the settlement will make AstraZeneca the latest in a series of drug manufacturers that have faced large exposures due to allegations of promoting off-label uses of drugs.
$520 Million Settlement Expected in AstraZeneca Off-Label Marketing Case
The Unites States Department of Justice is expected to announce shortly a settlement with AstraZeneca plc over allegations that the drug manufacturer improperly promoted off-label uses of its antipsychotic drug, Seroquel. Federal and state authorities have been investigating allegations that AstraZeneca promoted the use of Seroquel for purposes not approved by the Food and Drug Administration. The company has also faced allegations that it promoted favorable research while not disclosing studies linking Seroquel to an increased risk of diabetes.